Martin Marino Purchases 52,500 Shares of Microbix Biosystems (TSE:MBX) Stock

Microbix Biosystems Inc. (TSE:MBX) Director Martin Marino acquired 52,500 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was purchased at an average cost of C$0.24 per share, for a total transaction of C$12,600.00. Following the completion of the acquisition, the director owned 1,744,167 shares in the company, valued at approximately C$418,600.08. This represents a 3.10% increase in their ownership of the stock.

Martin Marino also recently made the following trade(s):

• On Monday, December 22nd, Martin Marino acquired 100,000 shares of Microbix Biosystems stock. The shares were purchased at an average price of C$0.23 per share, for a total transaction of C$23,000.00.

Microbix Biosystems Stock Up 2.3%

MBX opened at C$0.22 on Monday. The stock has a fifty day moving average of C$0.24 and a 200-day moving average of C$0.25. The company has a market capitalization of C$30.54 million, a P/E ratio of -13.75 and a beta of 0.03. Microbix Biosystems Inc. has a fifty-two week low of C$0.21 and a fifty-two week high of C$0.55. The company has a debt-to-equity ratio of 22.61, a quick ratio of 5.57 and a current ratio of 7.15.

Microbix Biosystems (TSE:MBX) last released its quarterly earnings results on Thursday, December 18th. The company reported C($0.01) EPS for the quarter. Microbix Biosystems had a return on equity of 12.65% and a net margin of 13.86%.The business had revenue of C$3.74 million for the quarter. On average, equities analysts expect that Microbix Biosystems Inc. will post 0.02 EPS for the current year.

Microbix Biosystems Company Profile

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.